<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ACETYLCYSTEINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ACETYLCYSTEINE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Tear deficiency</span>,
                <span class="indication">Impaired or abnormal mucus production</span>,
            </h4>
            <p class="specificity"><span class="route">To the eye</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 3&#8211;4 times a day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Paracetamol overdosage</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (body-weight 40 kg and above)</strong><br/>
                150 mg/kg over 1 hour, dose to be administered in 200 mL Glucose Intravenous Infusion 5%, then 50 mg/kg over 4 hours, to be started immediately after completion of first infusion, dose to be administered in 500 mL Glucose Intravenous Infusion 5%, then 100 mg/kg over 16 hours, to be started immediately after completion of second infusion, dose to be administered in 1 litre Glucose Intravenous Infusion 5%.</li>
              <li class="dose child"><strong>For children (body-weight up to 20 kg)</strong><br/>
                Initially 150 mg/kg over 1 hour, dose to be administered in 3 mL/kg glucose 5%, followed by 50 mg/kg over 4 hours, dose to be administered in 7 mL/kg glucose 5%, then 100 mg/kg over 16 hours, dose to be administered in 14 mL/kg glucose 5%.</li>
              <li class="dose child"><strong>For children (body-weight 20&#8211;39 kg)</strong><br/>
                Initially 150 mg/kg over 1 hour, dose to be administered in 100 mL glucose 5%, followed by 50 mg/kg over 4 hours, dose to be administered in 250 mL glucose 5%, then 100 mg/kg over 16 hours, dose to be administered in 500 mL glucose 5%.</li>
              <li class="dose child"><strong>For children (body-weight 40 kg and above)</strong><br/>
                150 mg/kg over 1 hour, dose to be administered in 200 mL Glucose Intravenous Infusion 5%, then 50 mg/kg over 4 hours, to be started immediately after completion of first infusion, dose to be administered in 500 mL Glucose Intravenous Infusion 5%, then 100 mg/kg over 16 hours, to be started immediately after completion of second infusion, dose to be administered in 1 litre Glucose Intravenous Infusion 5%.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>







      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> hypersensitivity-like reactions, rashes, slight increase in INR and prothrombin time, anaphylaxis in children, hypersensitivity-like reactions, rashes,
              </p>
        
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
                <p class="title">Hypersensitivity-like reactions</p>
              <p>Hypersensitivity-like reactions managed by reducing infusion rate or suspending until reaction settled (rash also managed by giving antihistamine; acute asthma managed by giving nebulised shortacting beta<sub>2</sub>agonist)&#8212;contact the National Poisons Information Service if reaction severe.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>For <i>oral </i>administration, use oral granules, <i>or</i> dilute injection solution (200&#8239;mg/mL) to a concentration of 50&#8239;mg/mL; orange or blackcurrant juice or cola drink may be used as a diluent to mask the bitter taste.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>Glucose 5% is preferred fluid; Sodium Chloride 0.9% is an alternative if Glucose 5% unsuitable.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i> (<i>Parvolex</i>
            <tm tmtype="reg"/>), give continuously in Glucose 5% or Sodium chloride 0.9%. Glucose Intravenous Infusion 5% is the preferred fluid; Sodium Chloride Intravenous Infusion 0.9% is an alternative if Glucose Intravenous Infusion 5% is unsuitable.</p>
            </section>
      </section>




      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>With intravenous use:</strong>
            asthma (see Side-effects for management of asthma but do not delay acetylcysteine treatment)
          </li>
          <li>
              <strong>With intravenous use:</strong>
            atopy
          </li>
          <li>
              <strong>With intravenous use:</strong>
            may slightly increase INR
          </li>
          <li>
              <strong>With intravenous use:</strong>
            may slightly increase prothrombin time
          </li>
          <li>
              <strong>With oral use:</strong>
            asthma in children
          </li>
          <li>
              <strong>With oral use:</strong>
            history of peptic ulceration in children
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>Not licensed for use in meconium ileus or for distal intestinal obstructive syndrome in children with cystic fibrosis.</p>
            </section>
      </section>










      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ACETYLCYSTEINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            granules,
            tablet,
            eye drops,
            effervescent tablet,
            oral solution,
            capsule,
            liquid,

            <div id="PHP77940"><a href="../medicinalForm/PHP77940.html" data-target="#PHP77940" data-action="load">Tablet</a></div>
            <div id="PHP75308"><a href="../medicinalForm/PHP75308.html" data-target="#PHP75308" data-action="load">Effervescent tablet</a></div>
            <div id="PHP77109"><a href="../medicinalForm/PHP77109.html" data-target="#PHP77109" data-action="load">Capsule</a></div>
            <div id="PHP77279"><a href="../medicinalForm/PHP77279.html" data-target="#PHP77279" data-action="load">Granules</a></div>
            <div id="PHP76331"><a href="../medicinalForm/PHP76331.html" data-target="#PHP76331" data-action="load">Solution for infusion</a></div>
            <div id="PHP76059"><a href="../medicinalForm/PHP76059.html" data-target="#PHP76059" data-action="load">Eye drops</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
